Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts

robot
Abstract generation in progress

UBS has upgraded Biogen Inc. (BIIB) to Buy from Neutral, increasing its price target to $225, citing upcoming pipeline catalysts within the next 12-15 months that are expected to drive the stock higher into 2027. The firm specifically highlighted potential upside from BIIB080 tau data and Phase III litifilimab data in systemic lupus. This upgrade follows a similar move by Wells Fargo, which also recently upgraded Biogen to Overweight with a $250 price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin